Concept · medicine
Asthma control and inflammatory phenotypes
6 studiesEvidence last moved Sep 24, 2026
Asthma is a chronic airway disease whose control varies widely between patients and whose underlying airway inflammation comes in different types (phenotypes), such as eosinophilic or neutrophilic. This page draws on a multinational patient survey, a sputum phenotyping series, two early-phase antibody trials, a cross-sectional COPD study and a pooled birth-cohort study of spirometry from childhood to adulthood.
Students often picture asthma as one disease treated with the same inhalers, and assume that a drug hitting its biological target will help. The evidence here shows that control is frequently poor, that inflammation types differ, and that lowering a biomarker is not the same as improving patients' outcomes.
Studies
6
Findings
6
6 supporting · 0 challenging · 5 qualifying citations
Open tensions
1
Latest change
Concept page published
Asthma control and inflammatory phenotypes
Currently
What we know
- Being on a preventer inhaler does not mean asthma is controlled, and patients underestimate poor control.
- Asthma inflammation comes in types, and a blood test can hint at one type but not the other.
- A drug can move a biomarker without helping patients.
- Early-phase trials establish safety; efficacy signals from them are preliminary.
- Earlier asthma marks a more flare-prone form of COPD.
Largest unresolved question
Biologic trials in this set were run in different asthma populations: MEDI-528 in mild asthma showed early hints of benefit on exercise challenge, while quilizumab in severe uncontrolled allergic asthma failed, and its own earlier promising allergen-challenge studies had been in mild asthma. Different drugs, targets and severities mean this is a limit on generalising from mild to severe disease rather than a direct conflict.
Common misconceptions
If a patient takes a daily preventer inhaler, their asthma is under control.
Among patients on regular inhaled corticosteroids, only 28% were well controlled, and during worsenings most increased their rescue inhaler first and their steroid only later.
A drug that clearly lowers its target biomarker (such as IgE) will reduce asthma attacks.
Quilizumab cut IgE by 30-40% yet failed on exacerbations and lung function in a phase II RCT; biomarker change is a surrogate, not the outcome.
Asthma is one type of airway inflammation, so blood counts tell you the airway picture in general.
Sputum showed eosinophilic, paucigranulocytic and neutrophilic types; blood eosinophils tracked eosinophilic inflammation moderately, but blood neutrophils barely tracked neutrophilic inflammation.
Related
Claim ledger
What the evidence shows
Drawn from 6 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.
Being on a preventer inhaler does not mean asthma is controlled, and patients underestimate poor control.
In a telephone survey of 3,415 patients in 11 countries on daily inhaled corticosteroids, only 28% had well-controlled asthma by questionnaire score and 74% had used their rescue inhaler every day in the past week, yet most with uncontrolled asthma rated their control as fairly good.
- How well controlled is asthma in people on daily inhalers?— Self-reported, cross-sectional, no lung-function measurement; industry-sponsored.
Asthma inflammation comes in types, and a blood test can hint at one type but not the other.
In 508 clinic patients with induced sputum, 42% had eosinophilic, 40% paucigranulocytic, 16% neutrophilic and 3% mixed inflammation; a blood eosinophil cut-off of 220/mm3 identified eosinophilic airways with 77% sensitivity and 70% specificity, about as well as exhaled NO, but blood neutrophils were a poor guide to neutrophilic asthma.
- Can a blood test reveal what kind of airway inflammation asthma has?— Retrospective single specialist clinic; phenotype measured once.
A drug can move a biomarker without helping patients.
Hitting a biological target did not translate into clinical benefit in a phase II RCT: quilizumab lowered IgE by 30-40% in severe uncontrolled allergic asthma but did not meaningfully reduce exacerbations (best arm a non-significant 19.6% reduction) or improve lung function, and the trial was stopped for lack of efficacy.
Early-phase trials establish safety; efficacy signals from them are preliminary.
Small phase 2a RCTs of the anti-IL-9 antibody MEDI-528 in mild asthma found adverse events similar to placebo, with only a hint of reduced exercise-induced bronchoconstriction in a handful of participants.
- Is an antibody against IL-9 safe to give people with asthma?— 36 and 11 participants; exercise result from one time point with a post hoc responder analysis.
Earlier asthma marks a more flare-prone form of COPD.
Asthma history changes the course of COPD: among 915 COPDGene smokers with COPD, the 13% with asthma before age 40 had similar lung function but worse quality of life and were more than three times as likely to be frequent exacerbators.
- Is COPD worse in people who also have asthma?— Cross-sectional, self-reported asthma diagnosis and recalled exacerbations.
Childhood lung impairment is not fixed, but asthma predicts it staying.
Impaired spirometry in childhood often recovers: in three pooled UK birth cohorts, about a third of children with an obstructive and half with a restrictive pattern had normal, stable lung function by early adulthood, while maternal smoking in pregnancy and current asthma raised the risk of persistent obstruction.
Debates
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.
Biologic trials in this set were run in different asthma populations: MEDI-528 in mild asthma showed early hints of benefit on exercise challenge, while quilizumab in severe uncontrolled allergic asthma failed, and its own earlier promising allergen-challenge studies had been in mild asthma. Different drugs, targets and severities mean this is a limit on generalising from mild to severe disease rather than a direct conflict.
Biologic trials in this set were run in different asthma populations: MEDI-528 in mild asthma showed early hints of benefit on exercise challenge, while quilizumab in severe uncontrolled allergic asthma failed, and its own earlier promising allergen-challenge studies had been in mild asthma. Different drugs, targets and severities mean this is a limit on generalising from mild to severe disease rather than a direct conflict.
- Is an antibody against IL-9 safe to give people with asthma?
- Can blocking IgE-making B cells prevent asthma attacks?
Study Role Design N Population Outcome Is an antibody against IL-9 safe to give people with asthma? Supports RCTTwo randomized, double-blind, placebo-controlled phase 2a trials: study 1 escalated weight-based doses (3:1 drug:placebo); study 2 tested a fixed 50 mg dose (2:1) with exercise challenge and was halted early. No single N: 36 adults randomized in study 1 (all included in safety analyses) and 11 in study 2 (9 evaluable for the exercise-challenge outcome). Adults with mild persistent asthma (study 1) or stable mild-to-moderate asthma with exercise-induced bronchoconstriction (study 2), recruited at US multicentre sites Primary: safety and tolerability (adverse events) of repeated subcutaneous MEDI-528; secondary/exploratory: pharmacokinetics, anti-drug antibodies, exercise-induced fall in FEV1, exacerbations, symptoms and quality of life Can blocking IgE-making B cells prevent asthma attacks? Supports RCTPhase II, multinational, double-blind, placebo-controlled RCT; three quilizumab dosing regimens vs placebo (1:1:1:1) for 36 weeks plus 48 weeks of follow-up N=578 · 578 adults randomised across four arms (433 quilizumab, 145 placebo) Adults aged 18-75 with allergic asthma uncontrolled despite high-dose inhaled corticosteroids plus a second controller, with at least one recent exacerbation, at sites in 14 countries Primary: annualised rate of asthma exacerbations to week 36; secondary: FEV1, symptom scores, rescue inhaler use, night awakenings; also IgE levels, biomarker subgroups and safety
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Timeline
How understanding moved
Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.
2026
Concept page published
Asthma control and inflammatory phenotypes
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Rewordings are not listed.
- Concept page published
Papers
5 studies in this library bear on Asthma control and inflammatory phenotypes, ordered by citations.
- How well controlled is asthma in people on daily inhalers?
Most people taking daily preventer inhalers still had poorly controlled asthma, and when symptoms worsened they reached for their rescue inhaler first and increased their preventer only late.
- Is COPD worse in people who also have asthma?
Smokers with COPD who had asthma earlier in life had similar lung function to those with COPD alone but worse quality of life and far more frequent flare-ups.
- Can a blood test reveal what kind of airway inflammation asthma has?
A routine blood eosinophil count identified eosinophilic airway inflammation about as well as exhaled nitric oxide, but blood neutrophils were a poor guide to neutrophilic asthma.
- Is an antibody against IL-9 safe to give people with asthma?
Repeated injections of an experimental anti-IL-9 antibody were tolerated about as well as placebo in people with mild asthma, with early hints that it might blunt exercise-triggered airway narrowing.
- Can blocking IgE-making B cells prevent asthma attacks?
Quilizumab, an antibody that targets the B cells that make IgE, lowered IgE levels by about a third but did not reduce asthma attacks or improve breathing in adults with hard-to-control allergic asthma.
Compare studies
Select 2–10 studies. Design and N are labels, not a ranking.
Nothing selected yet.
Questions
What is still open
Biologic trials in this set were run in different asthma populations: MEDI-528 in mild asthma showed early hints of benefit on exercise challenge, while quilizumab in severe uncontrolled allergic asthma failed, and its own earlier promising allergen-challenge studies had been in mild asthma. Different drugs, targets and severities mean this is a limit on generalising from mild to severe disease rather than a direct conflict.
Ask PaperFren about Asthma control and inflammatory phenotypes
Study this conceptflashcards and short-answer questions
Using the quilizumab and MEDI-528 trials, explain why phase II results must be interpreted cautiously.
The MEDI-528 trials were small (36 and 11 participants), designed mainly for safety, and their exercise-challenge benefit came from a few people at one time point with a post hoc responder analysis, so the efficacy signal is preliminary. Quilizumab, tested in 578 adults with severe allergic asthma, showed clear target engagement (IgE down 30-40%) but no meaningful reduction in exacerbations and was stopped for lack of efficacy. Together they show that safety data, surrogate markers and small subgroups in mild disease do not reliably predict clinical benefit in severe disease.
How well can a blood test identify the type of airway inflammation in asthma?
In a retrospective series of 508 clinic patients with induced sputum, blood eosinophils correlated moderately with sputum eosinophils (r = 0.6), and a cut-off of 220/mm3 gave 77% sensitivity and 70% specificity, similar to exhaled NO. Blood neutrophils, however, correlated weakly with sputum neutrophils, and a prediction equation for neutrophilic asthma agreed poorly in validation. The data come from one specialist clinic with a single measurement, and the study did not test whether treating by blood counts improves outcomes.